Jannine P. Balakid

Jannine P. Balakid

Auto-generated profile, based on publicly available information

Jannine P. Balakid

Department of Neurological Surgery, University California, San Francisco, San Francisco, CA, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2026 in Nature Medicine
Verified
Journal Article
Open access
KLKenneth H. Louie
Kenneth H. Louie
JBJannine P. Balakid
Jannine P. Balakid
JBJessica E. Bath
Jessica E. Bath
SSSeongmi Song
Seongmi Song
HAHamid Fekri Azgomi
Hamid Fekri Azgomi
DWDoris D. Wang
Doris D. Wang
A randomized crossover study of five patients with Parkinson’s disease (PD) demonstrates that gait-synchronized adaptive deep brain stimulation is feasible and safe, and reduces falls compared with continuous stimulation. Gait dysfunction in PD is a major source of disability and is often insufficiently treated by continuous deep brain stimulation (cDBS). Although adaptive DBS (aDBS) has shown efficacy for other motor symptoms using β-based, state-driven neural signals, gait is a dynamic, cyclical behavior that may require temporally precise modulation. Here we evaluated a behavior-contingent aDBS approach that synchronizes stimulation to gait phase. We reported a single-center, blinded, randomized, crossover study evaluating the feasibility of identifying patient-specific biomarkers to drive aDBS. The primary outcome was feasibility of successful identification of gait-phase biomarkers to implement aDBS. Five participants with PD undergoing pallidal DBS and subdural electrode paddle implantation were enrolled. We successfully identified personalized gait-phase biomarkers from cortical or pallidal field potentials in all five patients and embedded them into a bidirectional neurostimulator. During acute in-clinic testing, aDBS improved step variability and step symmetry versus cDBS. Three participants subsequently completed a double-blinded, multi-day crossover phase. In this setting, aDBS maintained general motor symptom control, reduced falls and yielded patient-specific gait improvements. No adverse events occurred and aDBS was well tolerated. These findings establish the feasibility of biomarker-driven, movement-synchronized neuromodulation and support the development of a larger randomized trial to determine clinical efficacy. ClinicalTrial.gov registration: NCT04675398 .

12 March 2025 in Research Square
Verified
Preprint
Open access
PDF file
DWDoris Wang
Doris Wang
RRRithvik Ramesh
Rithvik Ramesh
HAHamid Fekri Azgomi
Hamid Fekri Azgomi
KLKenneth Louie
Kenneth Louie
JBJannine Balakid
Jannine Balakid
JMJacob Marks
Jacob Marks
Movement decoding from invasive human recordings typically relies on a distributed system employing advanced machine learning algorithms programmed into an external computer for state classification. These brain-computer interfaces are limited to short-term studies in laboratory settings that may not reflect behavior and neural states in the real world. The development of implantable devices with sensing capabilities is revolutionizing the study and treatment of brain circuits. However, it is unknown whether these devices can decode natural movement state from recorded neural activity or accurately classify states in real-time using on-board algorithms. Here, using a totally implanted sensing-enabled neurostimulator to perform long-term, at-home recordings from the motor cortex and pallidum of four subjects with Parkinson’s disease, we successfully identified highly sensitive and specific personalized signatures of gait state, as determined by wearable sensors. Additionally, we demonstrated the feasibility of using at-home data to generate biomarkers compatible with the classifier embedded on-board the neurostimulator. These findings offer a pipeline for ecologically valid movement biomarker identification that can advance therapy across a variety of diseases.